World Hepatitis Day: improving care for those living with HCV in the DTES

Today is World Hepatitis Day, an annual opportunity to raise awareness of the global burden of viral hepatitis, a liver inflammation, and to spark action. This year’s theme is ‘I Can’t Wait’, which highlights the urgency from the global community to improve access to life-saving treatments.

Recent estimates by the World Health Organization (WHO) say 58 million people are chronically infected with HCV while 290,000 die annually from HCV-related liver diseases. In Canada, HCV affects 250,000 people, of which over 40 percent are unaware of their infection.

Around the world, every 30 seconds someone dies from a hepatitis-related illness, despite the fact that the hepatitis C virus (HCV) is now generally considered a curable disease. Relatively new and well-tolerated direct-acting antivirals (DAAs) have a cure rate of 95 per cent. However, there are still significant barriers to treatment for those in need.

The BC Centre for Excellence in HIV-AIDS at St. Paul’s Hospital is raising awareness of HCV and its treatment in several ways. Each follows the Treatment as Prevention® (TasP®) strategy pioneered by the BC-CfE and proven repeatedly to be effective. TasP® is based on the concept that early access to testing and immediate, sustained access to treatment improves quality of life and longevity, while curbing transmission. 

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below